Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (22)
Ying Wei, Sonia Erfani, David Schweer, Rafael de Gouvea, Javeria Qadir, Junfeng Shi, Kai Cheng, Dabao Wu, Rolf Craven, Yadi Wu, Thibault Olivier, Lauren A. Baldwin, Binhua Zhou, Ying Zhou, Weidong Zhao, Burton B. Yang, Frederick R. Ueland & Xiuwei H. Yang. (2023) Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies. Molecular Therapy - Oncolytics 28, pages 293-306.
Crossref
Crossref
Zahra AvanJavad Biabani ArdakaniFereshteh Talebpour AmiriSeyed Mohammad AbediSeyed Jalal Hosseinimehr. (2022)
The Potential Usefulness of
99m
Tc-HYNIC-(Ser)
3
-LTVPWY Peptide for Predicting HER2 Status Alteration After Chemotherapy in Ovarian Tumor-Bearing Mice
. Cancer Biotherapy and Radiopharmaceuticals 37:9, pages 862-869.
Crossref
Crossref
Naamit Deshet-Unger, Galit Horn, Moran Rawet-Slobodkin, Tova Waks, Ido Laskov, Nadav Michaan, Yael Raz, Vered Bar, Adi Zundelevich, Sara Aharon, Lubov Turovsky, Giuseppe Mallel, Seth Salpeter, Guy Neev, Kenneth Samuel Hollander, Ben-Zion Katz, Dan Grisaru & Anat Globerson Levin. (2022) Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. Biomedicines 10:9, pages 2216.
Crossref
Crossref
Daniel A. Vallera, Felix Oh, Behiye Kodal, Peter Hinderlie, Melissa A. Geller, Jeffrey S. Miller & Martin Felices. (2021) A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer. Cancers 13:16, pages 3994.
Crossref
Crossref
Monika Kressin, Daniela Fietz, Sven Becker & Klaus Strebhardt. (2021) Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer. Cells 10:5, pages 1176.
Crossref
Crossref
Olivia D. Lara, Emine Bayraktar, Paola Amero, Shaolin Ma, Cristina Ivan, Wei Hu, Ying Wang, Lingegowda S. Mangala, Prasanta Dutta, Pratip Bhattacharya, Ana Tari Ashizawa, Gabriel Lopez-Berestein, Cristian Rodriguez-Aguayo & Anil K. Sood. (2020) Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget 11:29, pages 2819-2833.
Crossref
Crossref
Radek Indra, Petr Pompach, Václav Martínek, Paulína Takácsová, Katarína Vavrová, Zbyněk Heger, Vojtěch Adam, Tomáš Eckschlager, Kateřina Kopečková, Volker Manfred Arlt & Marie Stiborová. (2019) Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation. International Journal of Molecular Sciences 20:14, pages 3392.
Crossref
Crossref
Babak Nami, Hamid Maadi & Zhixiang Wang. (2019) The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation. Cancers 11:3, pages 375.
Crossref
Crossref
Faye R. Harris, Piyan Zhang, Lin Yang, Xiaonan Hou, Konstantinos Leventakos, Saravut J. Weroha, George Vasmatzis & Irina V. Kovtun. (2018)
Targeting
HER
2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
. Molecular Oncology 13:2, pages 132-152.
Crossref
Crossref
Elisa Zanini, Louay S. Louis, Jane Antony, Evdoxia Karali, Imoh S. Okon, Arthur B. McKie, Sebastian Vaughan, Mona El-Bahrawy, Justin Stebbing, Chiara Recchi & Hani Gabra. (2017) The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. Molecular Cancer Therapeutics 16:10, pages 2246-2256.
Crossref
Crossref
Luisa Paris, Franca Podo, Francesca Spadaro, Laura Abalsamo, Maria Elena Pisanu, Alessandro Ricci, Serena Cecchetti, Luisa Altabella, Maria Buoncervello, Ludmila Lozneanu, Marina Bagnoli, Carlo Ramoni, Silvana Canevari, Delia Mezzanzanica, Egidio Iorio & Rossella Canese. (2017)
Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and
in vivo
tumor growth in a highly tumorigenic ovarian cancer model
. Oncotarget 8:33, pages 55022-55038.
Crossref
Crossref
Daniel Veigel, Renate Wagner, Gerald Stübiger, Michael Wuczkowski, Martin Filipits, Reinhard Horvat, Bellinda Benhamú, María Luz López-Rodríguez, Asha Leisser, Peter Valent, Michael Grusch, Fausto G. Hegardt, Jordi García, Dolors Serra, Nelly Auersperg, Ramón Colomer & Thomas W. Grunt. (2015) Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. International Journal of Cancer 136:9, pages 2078-2090.
Crossref
Crossref
Eleonora Teplinsky & Franco Muggia. (2014) Targeting HER2 in ovarian and uterine cancers: Challenges and future directions. Gynecologic Oncology 135:2, pages 364-370.
Crossref
Crossref
Donavon Hiss. (2012) Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways. Journal of Oncology 2012, pages 1-23.
Crossref
Crossref
Katharina Tomek, Renate Wagner, Franz Varga, Christian F. Singer, Heidrun Karlic & Thomas W. Grunt. (2011) Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer. Molecular Cancer Research 9:12, pages 1767-1779.
Crossref
Crossref
M. HOOPMANN, K. SACHSE, M.M. VALTER, M. BECKER, R. NEUMANN, M. ORTMANN, U.-J. GÖHRING, A. THOMAS, P. MALLMANN & T. SCHÖNDORF. (2010) Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. European Journal of Cancer Care 19:6, pages 809-815.
Crossref
Crossref
Irina Nazarenko, Marcel Jenny, Jana Keil, Cornelia Gieseler, Karen Weisshaupt, Jalid Sehouli, Stefan Legewie, Lena Herbst, Wilko Weichert, Silvia Darb-Esfahani, Manfred Dietel, Reinhold Schäfer, Florian Ueberall & Christine Sers. (2010) Atypical Protein Kinase C ζ Exhibits a Proapoptotic Function in Ovarian Cancer. Molecular Cancer Research 8:6, pages 919-934.
Crossref
Crossref
MACIEJ MALECKI, ROBERT PROCZKA, JOANNA CHOROSTOWSKA-WYNIMKO, PAWEŁ SWOBODA, ANNA DELBANI & JAN PACHECKA. (2010) Recombinant adeno-associated viruses (rAAV2) facilitate the intraperitoneal gene delivery to cancer cells. Oncology Letters 1:1, pages 177-180.
Crossref
Crossref
Federica Barbieri, Adriana Bajetto & Tullio Florio. (2010) Role of Chemokine Network in the Development and Progression of Ovarian Cancer: A Potential Novel Pharmacological Target. Journal of Oncology 2010, pages 1-15.
Crossref
Crossref
Philip M. Grimley, Rayna K. Matsuno, Philip S. Rosenberg, Donald E. Henson, Arnold M. Schwartz & William F. Anderson. (2009) Qualitative Age Interactions between Low-grade and High-grade Serous Ovarian Carcinomas. Cancer Epidemiology, Biomarkers & Prevention 18:8, pages 2256-2261.
Crossref
Crossref
Susana Banerjee & Martin Gore. (2009) The Future of Targeted Therapies in Ovarian Cancer. The Oncologist 14:7, pages 706-716.
Crossref
Crossref
Thomas W. Grunt, Renate Wagner, Michael Grusch, Walter Berger, Christian F. Singer, Brigitte Marian, Christoph C. Zielinski & Ruth Lupu. (2009) Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochemical and Biophysical Research Communications 385:3, pages 454-459.
Crossref
Crossref